ReviewHematology/oncology clinics of North America2009
Applications of genomics in melanoma oncogene discovery.
Review in Hematology/oncology clinics of North America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.The Journal of dermatology · 2018Trial
- Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- An overview of benefits and risks of chronic melanocortin-1 receptor activation.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- The Emerging Burden of Genetic Instability and Mutation in Melanoma: Role of Molecular Mechanisms.Cancers · 2022Article
- Skin pigmentation polymorphisms associated with increased risk of melanoma in a case-control sample from southern Brazil.BMC cancer · 2020Article
- Review
- Molecular background of skin melanoma development and progression: therapeutic implications.Postepy dermatologii i alergologii · 2019Review
- Article
- Mutational status of naevus-associated melanomas.The British journal of dermatology · 2015Article
- DNA methylation characteristics of primary melanomas with distinct biological behaviour.PloS one · 2014Article
- Article
- The evolution of S100B inhibitors for the treatment of malignant melanoma.Future medicinal chemistry · 2013Review
- Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The identification of recurrent alterations in the melanoma genome has provided key insights into the biology of melanoma genesis and progression. These discoveries have come about as a result of the systematic deployment and integration of diverse genomic technologies, including DNA sequencing, chromosomal copy number analysis, and gene expression profiling. Here, the discoveries of several key melanoma oncogenes affecting critical cell pathways are described and the role played by evolving genomics technologies in melanoma oncogene discovery is examined. These advances are being exploited to improve prognosis and treatment of melanoma patients through the development of genome-based diagnostic and targeted therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.